CLRB · XBRL financial data

Cellectar Biosciences financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CLRB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	7,313	6,991*	7,088	7,345	5,493	6,209*	3,427	2,390	2,523	3,159*	3,007	4,557
General and administrative	2,101	5,557*	4,913	6,358	7,834	6,536*	2,974	3,648	2,327	2,532*	2,787	2,639
Operating income (loss)	(9,413)	(12,548)*	(12,001)	(13,704)	(13,328)	(12,745)*	(6,401)	(6,038)	(4,851)	(5,691)*	(5,794)	(7,196)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	—	—	—
Net income (loss)	(13,732)	(12,236)*	(26,642)	(919)	(14,665)	(2,355)*	(6,604)	(5,448)	(4,444)	(5,295)*	(5,654)	(6,931)
Earnings per share, basic‡ USD per share	(36.67)	(24.55)*	(27.58)	(0.91)	(11.21)	—	(4.24)	(3.39)	(1.41)	—	(1.33)	(0.57)
Earnings per share, diluted‡ USD per share	(36.67)	(24.55)*	(27.58)	(5.45)	(12.12)	—	(4.24)	(3.39)	(1.41)	—	(1.33)	(0.57)
Weighted average shares, basic‡ thousands of shares	373	496*	968	1,182	1,298	1,383*	1,521	1,609	3,162	—	4,240	12,232
Weighted average shares, diluted‡ thousands of shares	373	496*	968	1,236	1,313	1,383*	1,521	1,609	3,162	—	4,240	12,232

‡ Per-share figures and share counts are adjusted for the 1-for-30.3030303030303 stock split (June 2025); filings made before it reported them unadjusted.

Fiscal quarters (CLRB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	18,986	9,565	40,031	25,869	34,263	23,289	13,905	11,041	12,554	13,196	8,347	33,994
Prepaid and other current assets	1,123	888	1,337	2,036	1,636	962	987	1,577	1,067	842	920	884
Total current assets	20,110	10,453	41,368	27,905	35,899	24,250	14,893	12,618	13,622	14,038	9,267	34,878
Property and equipment, net	894	1,090	1,023	979	910	757	701	648	595	549	340	304
Right-of-use asset	518	502	487	471	454	437	419	400	381	361	1,483	1,434
Total assets	21,551	12,076	42,908	29,385	37,293	25,474	16,042	13,695	14,628	14,978	11,120	36,639
Accounts payable	—	5,620	—	—	—	4,105	—	—	—	1,441	—	—
Total current liabilities	16,471	25,359	28,551	15,168	20,314	9,388	6,021	5,867	4,912	4,750	4,874	5,238
Lease liability, non-current	513	494	474	454	432	410	386	361	336	309	1,529	1,530
Total liabilities	16,984	25,853	29,025	15,622	20,746	9,797	6,407	6,228	5,248	5,059	6,403	6,767
Accumulated deficit	(210,034)	(202,761)	(229,403)	(230,322)	(244,987)	(247,342)	(253,946)	(259,394)	(263,838)	(269,134)	(274,787)	(281,718)
Total stockholders' equity	(13,353)	(15,159)	12,501	12,381	15,165	14,295	8,253	6,085	7,997	8,537	3,335	29,872
Total liabilities and equity	21,551	12,076	42,908	29,385	37,293	25,474	16,042	13,695	14,628	14,978	11,120	36,639
Common shares outstanding (cover page)‡ thousands of shares	406	1,065	1,183	1,339	1,362	1,521	1,521	3,192	4,240	4,240	7,992	9,452

‡ Per-share figures and share counts are adjusted for the 1-for-30.3030303030303 stock split (June 2025); filings made before it reported them unadjusted.

Fiscal quarters (CLRB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(13,732)	(12,236)*	(26,642)	(919)	(14,665)	(2,355)*	(6,604)	(5,448)	(4,444)	(5,295)*	(5,654)	(6,931)
Stock-based compensation	498*	1,084*	454	799*	1,534*	1,485*	563	565*	568*	568*	452	428*
Depreciation and amortization	41*	70*	88	66*	69*	69*	56	56*	52*	49*	—	—
Net cash from operating activities	(8,068)*	(9,596)*	(13,362)	(14,141)*	(9,167)*	(10,913)*	(9,383)	(5,116)*	(4,275)*	(4,344)*	(4,846)	(6,010)*
Purchases of property and equipment	—	267*	22	21*	0*	61*	—	—	—	year only	3	0*
Net cash from investing activities	—	(267)*	(22)	(21)*	0*	(61)*	—	—	—	year only	(3)	0*
Net cash from financing activities	22,499*	441*	43,849	0*	17,561*	0*	—	—	5,788*	4,992*	—	—
Net change in cash	13,833*	(9,421)*	30,466	(14,162)*	8,394*	(10,975)*	(9,383)	(2,864)*	1,513*	642*	(4,849)	25,647*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.